师资

董金堂
讲席教授
深圳市国家级领军人才
人类细胞生物和遗传学系主任
0755-88018032
dongjt@sustech.edu.cn

个人简介:

董金堂,南方科技大学医学院讲席教授,博士生导师。人类细胞生物和遗传学系主任。杰出青年基金获得者。深圳市国家级领军人才。1984年获南开大学生物学学士,1989获中国协和医科大学、中国医学科学院理学博士。美国国立卫生研究院和约翰霍普金斯大学医学院博士后。美国弗吉尼亚大学医学院助理教授、副教授。美国埃默里大学医学院副教授、教授。主持过二十余项中国和美国的科研项目。在包括Science和Nature系列杂志在内的国际学术刊物上发表论文近130篇。获得过多项国内和国际奖励。担任中国和美国政府不同部门的各种科研和人才项目的评审,多家国际学术刊物的副主编或编委。带领团队从事肿瘤发生发展的分子基础研究20多年,已经培养博士和博士后30余名。

 

研究领域:

肿瘤发生发展的分子基础及其转化应用研究:董金堂课题组利用遗传学、生物化学、细胞生物学、分子生物学、组织病理学等各种研究手段和各种肿瘤模型,了解前列腺癌发生和演进的生物学机制,并探索机制方面的发现在肿瘤检测和治疗方面的应用。

教学:

生物学硕士和博士生:肿瘤生物学;生物医学专业本科生:医学遗传学、细胞生物学。

 

工作经历:

1989年7月至1990年9月: 助理研究员,北京中国医学科学院肿瘤研究所。

1990年10月至1994年10月: 博士后, 美国北卡州研究三角公园美国国立卫生研究院环境与健康研究所分子癌变研究室 。

1994年10月到1996年9月: 博士后, 美国马里兰州巴尔的摩市约翰. 霍普金斯大学医学院肿瘤学中心。

1996年10月至2002年3月:助理教授、副教授(2001年7月),美国弗吉尼亚州夏洛丝维尔弗吉尼亚大学医学院病理系和生物化学和分子遗传学系。

2002年4月至2018年8月:副教授、教授、研究副主任、项目共同主任,美国乔治亚州亚特兰大市埃默里大学医学院,埃默里大学Winship肿瘤研究所。

2006年3月至2018年7月:南开大学生命科学学院教授(兼)。

2018年8月至今:讲席教授,南方科技大学医学院。

 

教育背景:

1980年9月至1984年7月: 天津南开大学生物系. 获理学学士学位;

1984年9月至1989年7月:北京中国医学科学院中国协和医科大学肿瘤研究所.获理学博士学位;

1990年10月至1994年10月: 博士后, 美国北卡州研究三角公园美国国立卫生研究院环境与健康研究所分子癌变研究室;

1994年10月至1996年9月: 博士后, 美国马里兰州巴尔的摩市约翰. 霍普金斯大学医学院肿瘤学中心。

 

已发表的学术论文目录(按年度顺序排列):

  1. Annab LA, Dong JT, Futreal PA, Satoh H, Oshimura M & Barrett JC. Growth and transformation suppressor genes for BHK Syrian hamster cells on human chromosomes 1 and 11. Mol Carcinog 6:280-288, 1992.

  2. Ichikawa T, Ichikawa Y, Dong JT, Hawkins AL, Griffin CA, Isaacs WB, Oshimura M, Barrett JC & Isaacs JT. Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res 52:3486-3490, 1992.

  3. Dong JT & Luo XM. Arsenic-induced DNA-strand breaks associated with DNA-protein crosslinks in human fetal lung fibroblasts. Mutat Res 302:97-102, 1993.

  4. Satoh H, Lamb PW, Dong JT, Everitt J, Boreiko C, Oshimura M & Barrett JC. Suppression of tumorigenicity of A549 lung adenocarcinoma cells by human chromosomes 3 and 11 introduced via microcell-mediated chromosome transfer. Mol Carcinog 7:157-164, 1993.

  5. Dong JT & Luo XM. Effects of arsenic on DNA damage and repair in human fetal lung fibroblasts. Mutat Res 315:11-15, 1994.

  6. Rinker-Schaeffer CW, Hawkins AL, Ru N, Dong JT, Stoica G, Griffin CA, Ichikawa T, Barrett JC & Isaacs JT. Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res 54:6249-6256, 1994.

  7. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT & Barrett JC. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268:884-886, 1995.

  8. Dong JT, Zhou CN & Luo XM. Induction of preneoplastic lesions by sodium arsenite in human fetal respiratory epithelia in organ culture. Environ Res 68:39-43, 1995.

  9. Dong JT, Rinker-Schaeffer CW, Ichikawa T, Barrett JC & Isaacs JT. Prostate cancer - biology of metastasis and its clinical implications. World J Urol 14:182-189, 1996.

  10. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC & Isaacs JT. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 56:4387-4390, 1996.

  11. Dong JT, Isaacs WB, Barrett JC & Isaacs JT. Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics 41:25-32, 1997.

  12. Gao AC, Lou W, Dong JT & Isaacs JT. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 57:846-849, 1997.

  13. Kawana Y, Komiya A, Ueda T, Nihei N, Kuramochi H, Suzuki H, Yatani R, Imai T, Dong JT, Imai T, Yoshie O, Barrett JC, Isaacs JT, Shimazaki J, Ito H, & Ichikawa T. Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Prostate 32:205-213, 1997.

  14. Dong JT, Sipe TW, Hyytinen ER, Li CL, Heise C, McClintock DE, Grant CD, Chung LW & Frierson HF, Jr. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 17:1979-1982, 1998.

  15. Suzuki H, Dong JT, Gao AC, Barrett JC & Isaacs JT. Identification of the rat homologue of KAI1 and its expression in Dunning rat prostate cancers. Prostate 37:253-260, 1998.

  16. Hyytinen ER, Frierson HF, Boyd JC, Chung LW & Dong JT. Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes Chromosomes Cancer 25:108-114, 1999.

  17. Hyytinen ER, Frierson HF, Sipe TW, Li CL, Degeorges A, Sikes RA, Chung LWK & Dong JT. Loss of heterozygosity and lack of mutations of the XPG/ERCC5 DNA repair gene at 13q33 in prostate cancer. Prostate 41:190-195, 1999.

  18. Lou W, Krill D, Dhir R, Becich ML, Dong JT, Frierson HF, Isaacs WB, Isaacs JT & Gao AC. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res 59:2329-2331, 1999.

  19. Dong JT, Chen C, Stultz BG, Isaacs JT & Frierson HF, Jr. Deletion at 13q21 is associated with aggressive prostate cancers. Cancer Res 60:3880-3883, 2000.

  20. Liu FS, Dong JT, Chen JT, Hsieh YT, Ho ESC & Hung MJ. Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma. Gynecol Oncol 78:10-15, 2000.

  21. Chen C, Brabham WW, Stultz BG, Frierson HF, Jr, Barrett JC, Sawyers CL, Isaacs JT & Dong JT. Defining a common region of deletion at 13q21 in human cancers. Genes Chromosomes Cancer 31:333–344, 2001.

  22. Chen C, Frierson HF, Jr., Haggerty PF, Theodorescu D, Gregory CW & Dong JT. An 800 kb region of deletion at 13q14 in human prostate and other carcinomas. Genomics 77:135-144, 2001.

  23. Dong JT, Boyd JC & Frierson HF, Jr. Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer. Prostate 49:166-171, 2001.

  24. Dong JT, Li CL, Sipe TW & Frierson HFJ. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin Cancer Res 7:304-308, 2001.

  25. Liu FS, Chen JT, Dong JT, Hsieh YT, Lin AJ, Ho ESC, Hung MJ & Lu CH. KAI1 metastasis suppressor gene is frequently down regulated in cervical carcinoma. Am J Pathol 159:1629-1634, 2001.

  26. Chen C, Bhalala HV, Qiao H & Dong JT. A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 21:6567-6572, 2002.

  27. Hyytinen ER, Saadut R, Chen C, Paull L, Koivisto PA, Vessella RL, Frierson HF & Dong JT. Defining the region(s) of deletion at 6q16-q22 in human prostate cancer. Genes Chromosomes Cancer 34:306-312, 2002.

  28. Liu FS, Chen JT, Dong JT, Hsieh YT, Lin AJ, Ho ES, Hung MJ & Lu CH. Author's Reply : KAI1 metastasis suppresor gene is frequently down-regulated in cervical carcinoma. Am J Pathol 160:1543, 2002.

  29. Chen C, Bhalala HV, Vessella RL & Dong JT. KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate 55:81-88, 2003.

  30. Chen C, Hyytinen ER, Sun X, Helin HJ, Koivisto PA, Frierson HF, Vessella RL & Dong JT. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol 162:1349-1354, 2003.

  31. Gao AC, Lou W, Dong JT, Barrett JC, Danielpour D & Isaacs JT. Defining regulatory elements in the human KAI1 (CD 82) metastasis suppressor gene. Prostate 57:256-260, 2003.

  32. Liu FS, Dong JT, Chen JT, Hsieh YT, Lin AJ, Ho ESC, Hung MJ & Lu CH. KAI1 metastasis suppressor protein is down-regulated during the progression of human endometrial cancer. Clin Cancer Res 9:1393-1398, 2003.

  33. Chen C, Zhou Y, Zhou Z, Sun X, Otto KB, Uht RM & Dong JT. Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells. Gene 330:133-142, 2004.

  34. Koivisto PA, Zhang X, Sallinen SL, Sallinen P, Helin HJ, Dong JT, Van Meir EG, Haapasalo H & Hyytinen ER. Absence of KLF6 gene mutations in human astrocytic tumors and cell lines. Int J Cancer 111:642-643, 2004.

  35. Wang R, Xu J, Saramaki O, Visakorpi T, Sutherland WM, Zhou J, Sen B, Lim SD, Mabjeesh N, Amin M, Dong JT, Petros JA, Nelson PS, Marshall FF, Zhau HE, & Chung LW. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res 64:1589-1594, 2004.

  36. Chen C, Sun X, Guo P, Dong XY, Sethi P, Cheng X, Zhou J, Ling J, Simons JW, Lingrel JB & Dong JT. Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J Biol Chem 280:41553-41561, 2005.

  37. Chen C, Sun X, Ran Q, Wilkinson KD, Murphy TJ, Simons JW & Dong JT. Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene 24:3319-3327, 2005.

  38. Guo GM, Huang XP, Dong JT, Caia Y, Xu X, Han YL, Wu M, Zhan QM & Wang MR. A novel region of deletion on 13q33-q34 in esophageal squamous cell carcinoma. Oncol Rep 14:1639-1646, 2005.

  39. Sun X, Frierson HF, Chen C, Li C, Ran Q, Otto KB, Cantarel BL, Vessella RL, Gao AC, Petros J, Miura Y, Simons JW & Dong JT. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet 37:407-412, 2005.

  40. Chen C, Benjamin MS, Sun X, Otto KB, Guo P, Dong XY, Bao Y, Zhou Z, Cheng X, Simons JW & Dong JT. KLF5 promotes cell proliferation and tumorigenesis through gene regulation in the TSU-Pr1 human bladder cancer cell line. Int J Cancer 118:1346-1355, 2006.

  41. Dong JT. Prevalent mutations in prostate cancer. J Cell Biochem 97:433-447, 2006.

  42. Dong XY, Chen C, Sun X, Guo P, Vessella RL, Wang RX, Chung LW, Zhou W & Dong JT. FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res 66:6998-7006, 2006.

  43. Liu M, Aneja R, Liu C, Sun L, Gao J, Wang H, Dong JT, Sarli V, Giannis A, Joshi HC & Zhou J. Inhibition of the mitotic kinesin Eg5 upregulates Hsp70 through the PI3K/Akt pathway in multiple myeloma cells. J Biol Chem 281:18090-18097, 2006.

  44. Sun X, Chen C, Vessella RL & Dong JT. Microsatellite instability and mismatch repair target gene mutations in cell lines and xenografts of prostate cancer. Prostate 66:660-666, 2006.

  45. Wu YP, Yang YL, Yang GZ, Wang XY, Luo ML, Zhang Y, Feng YB, Xu X, Han YL, Cai Y, Zhan QM, Wu M, Dong JT & Wang MR. Identification of chromosome aberrations in esophageal cancer cell line KYSE180 by multicolor fluorescence in situ hybridization. Cancer Genet Cytogenet 170:102-107, 2006.

  46. Zhong D, Morikawa A, Guo L, Colpaert C, Xiong L, Nassar A, Chen C, Lamb N, Dong JT & Zhou W. Homozygous deletion of SMAD4 in breast cancer cell lines and invasive ductal carcinomas. Cancer Biol Ther 5:601-607, 2006.

  47. Zhu N, Gu L, Findley HW, Chen C, Dong JT, Yang L & Zhou M. KLF5 interacts with P53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem 281:14711-14718, 2006.

  48. Chen C, Sun X, Guo P, Dong XY, Sethi P, Zhou W, Zhou Z, Petros J, Frierson HF, Vessella RL, Atfi A & Dong JT. Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene 26:2386-2394, 2007.

  49. Chen C, Zhou Z, Guo P & Dong JT. Proteasomal degradation of the KLF5 transcription factor through a ubiquitin-independent pathway. FEBS Lett 581:1124-1130, 2007.

  50. Chen C, Zhou Z, Ross JS, Zhou W & Dong JT. The amplified WWP1 gene is a potential molecular target in breast cancer. Int J Cancer 121:80-87, 2007.

  51. Sun X, Zhou Y, Otto KB, Wang M, Chen C, Zhou W, Subramanian K, Vertino PM & Dong JT. Infrequent mutation of ATBF1 in human breast cancer. J Cancer Res Clin Oncol 133:103-105, 2007.

  52. Dong XY, Rodriguez C, Guo P, Sun X, Talbot JT, Zhou W, Petros J, Li Q, Vessella RL, Kibel AS, Stevens VL, Calle EE & Dong JT. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet 17:1031-1042, 2008.

  53. Gao J, Huo L, Sun X, Liu M, Li D, Dong JT & Zhou J. The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem 283:8802-8809, 2008.

  54. Guo L, Zhong D, Lau S, Liu X, Dong XY, Sun X, Yang VW, Vertino PM, Moreno CS, Varma V, Dong JT & Zhou W. Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Mol Cancer Res 6:1421-1430, 2008.

  55. He S, Guo GM, Liu FX, Huang XP, Xu X, Cai Y, Han YL, Zhan QM, Wu M, Dong JT, Wang GQ & Wang MR. Molecular analysis in combination with iodine staining may contribute to the risk prediction of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 134:307-315, 2008.

  56. Liu M, Aneja R, Sun X, Xie S, Wang H, Wu X, Dong JT, Li M, Joshi HC & Zhou J. Parkin regulates Eg5 expression by Hsp70 ubiquitination-dependent inactivation of the c-Jun NH2-terminal kinase. J Biol Chem 283:35783-35788, 2008.

  57. Sun L, Gao J, Dong X, Liu M, Shi X, Liu C, Dong JT, Lu X, Li D & Zhou J. EB1 promotes Aurora-B kinase activity through blocking its inactivation by protein phosphatase 2A. Proc Natl Acad Sci U S A 105:7153-7158, 2008.

  58. Sun L, Li D, Dong X, Yu H, Dong JT, Zhang C, Lu X & Zhou J. Small-molecule inhibition of Aurora kinases triggers spindle checkpoint-independent apoptosis in cancer cells. Biochem Pharmacol 75:1027-1034, 2008.

  59. Yang YL, Chu JY, Luo ML, Wu YP, Zhang Y, Feng YB, Shi ZZ, Xu X, Han YL, Cai Y, Dong JT, Zhan QM, Wu M & Wang MR. Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Genes Chromosomes Cancer 47:127-136, 2008.

  60. Chen L, Zhu Z, Sun X, Dong XY, Wei J, Gu F, Sun YL, Zhou J, Dong JT & Fu L. Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis. Breast Cancer Res Treat 116:471-478, 2009.

  61. Dong JT & Chen C. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell Mol Life Sci 66:2691-2706, 2009.

  62. Dong XY, Guo P, Boyd J, Sun X, Li Q, Zhou W & Dong JT. Implication of snoRNA U50 in human breast cancer. J Genet Genomics 36:447-454, 2009.

  63. Guo P, Dong XY, Zhang X, Zhao KW, Sun X, Li Q & Dong JT. Pro-proliferative factor KLF5 becomes anti-proliferative in epithelial homeostasis upon signaling-mediated modification. J Biol Chem 284:6071-6078, 2009.

  64. Guo P, Dong XY, Zhao K, Sun X, Li Q & Dong JT. Opposing effects of KLF5 on the transcription of MYC in epithelial proliferation in the context of transforming growth factor beta. J Biol Chem 284:28243-28252, 2009.

  65. Guo P, Zhao KW, Dong XY, Sun X & Dong JT. Acetylation of KLF5 alters the assembly of p15 transcription factors in transforming growth factor-beta-mediated induction in epithelial cells. J Biol Chem 284:18184-18193, 2009.

  66. Liu R, Zheng HQ, Zhou Z, Dong JT & Chen C. KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization. J Biol Chem 284:16791-16798, 2009.

  67. Wang H, Liu B, Zhang C, Peng G, Liu M, Li D, Gu F, Chen Q, Dong JT, Fu L & Zhou J. Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism. J Pathol 218:76-85, 2009.

  68. Wang XC, Wu YP, Ye B, Lin DC, Feng YB, Zhang ZQ, Xu X, Han YL, Cai Y, Dong JT, Zhan QM, Wu M & Wang MR. Suppression of anoikis by SKP2 amplification and overexpression promotes metastasis of esophageal squamous cell carcinoma. Mol Cancer Res 7:12-22, 2009.

  69. Zheng HQ, Zhou Z, Huang J, Chaudhury L, Dong JT & Chen C. Kruppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1. Oncogene 28:3702-3713, 2009.

  70. Dong X, Liu F, Sun L, Liu M, Li D, Su D, Zhu Z, Dong JT, Fu L & Zhou J. Oncogenic function of microtubule end-binding protein 1 in breast cancer. J Pathol 220:361-369, 2010.

  71. Dong XY, Sun X, Guo P, Li Q, Sasahara M, Ishii Y & Dong JT. ATBF1 inhibits estrogen receptor (ER) function by selectively competing with AIB1 for binding to the ER in ER-positive breast cancer cells. J Biol Chem 285:32801-32809, 2010.

  72. Guo P, Dong XY, Zhao KW, Sun X, Li Q & Dong JT. Estrogen-induced interaction between KLF5 and estrogen receptor (ER) suppresses the function of ER in ER-positive breast cancer cells. Int J Cancer 126:81-89, 2010.

  73. Dong XY, Guo P, Sun X, Li Q & Dong JT. Estrogen up-regulates ATBF1 transcription but causes its protein degradation in estrogen receptor-alpha-positive breast cancer cells. J Biol Chem 286:13879-13890, 2011.

  74. Wang XX, Fu L, Li X, Wu X, Zhu Z & Dong JT. Somatic mutations of the mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers. Pathology Oncology Research 17:429-433, 2011.

  75. Wang XX, Zhu Z, Su D, Lei T, Wu X, Fan Y, Li X, Zhao J, Fu L, Dong JT & Fu L. Down-regulation of leucine zipper putative tumor suppressor 1 is associated with poor prognosis, increased cell motility and invasion, and epithelial-to-mesenchymal transition characteristics in human breast carcinoma. Hum Pathol 42:1410-1419, 2011.

  76. Zhang Z, Zhang B, Li W, Fu L, Fu L, Zhu Z & Dong JT. Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes Cancer 2:782-791, 2011.

  77. Zhao KW, Sikriwal D, Dong X, Guo P, Sun X & Dong JT. Oestrogen causes degradation of KLF5 by inducing the E3 ubiquitin ligase EFP in ER-positive breast cancer cells. Biochem J 437:323-333, 2011.

  78. Dong XY, Fu X, Fan S, Guo P, Su D & Dong JT. Oestrogen causes ATBF1 protein degradation through the oestrogen-responsive E3 ubiquitin ligase EFP. Biochem J 444:581-590, 2012.

  79. Hao JJ, Shi ZZ, Zhao ZX, Zhang Y, Gong T, Li CX, Zhan T, Cai Y, Dong JT, Fu SB, Zhan QM & Wang MR. Characterization of genetic rearrangements in esophageal squamous carcinoma cell lines by a combination of M-FISH and array-CGH: further confirmation of some split genomic regions in primary tumors. BMC Cancer 12:367, 2012.

  80. Li M, Fu X, Ma G, Sun X, Dong X, Nagy T, Xing C, Li J & Dong JT. Atbf1 regulates pubertal mammary gland development likely by inhibiting the pro-proliferative function of estrogen-ER signaling. PLoS One 7:e51283, 2012.

  81. Su D, Fu X, Fan S, Wu X, Wang XX, Fu L, Dong XY, Ni JJ, Zhu Z & Dong JT. Role of ERRF, a novel ER-related nuclear factor, in the growth control of ER-positive human breast cancer cells. Am J Pathol 180:1189-1201, 2012.

  82. Sun X, Fu X, Li J, Xing C, Martin DW, Zhang HH, Chen Z & Dong JT. Heterozygous deletion of Atbf1 by the Cre-loxP system in mice causes preweaning mortality. Genesis 50:819-827, 2012.

  83. Wu X, Zhu Z, Li W, Fu X, Su D, Fu L, Zhang Z, Luo A, Sun X & Dong JT. Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer. Breast Cancer Res 14:R73, 2012.

  84. Dong JT. Anticancer activities of PPARgamma in breast cancer are context-dependent. American Journal of Pathology 182:1972-1975, 2013.

  85. Hao JJ, Gong T, Zhang Y, Shi ZZ, Xu X, Dong JT, Zhan QM, Fu SB & Wang MR. Characterization of gene rearrangements resulted from genomic structural aberrations in human esophageal squamous cell carcinoma KYSE150 cells. Gene 513:196-201, 2013.

  86. Li M, Zhao D, Ma G, Zhang B, Fu X, Zhu Z, Fu L, Sun X & Dong JT. Upregulation of ATBF1 by progesterone-PR signaling and its functional implication in mammary epithelial cells. Biochem Biophys Res Commun 430:358-363, 2013.

  87. Liu R, Dong JT & Chen C. Role of KLF5 in hormonal signaling and breast cancer development. Vitam Horm 95:213-225, 2013.

  88. Martin-Garrido A, Williams HC, Lee M, Seidel-Rogol B, Ci X, Dong JT, Lassegue B, Martin AS & Griendling KK. Transforming growth factor beta inhibits platelet derived growth factor-induced vascular smooth muscle cell proliferation via Akt-independent, smad-mediated cyclin D1 downregulation. PLoS One 8:e79657, 2013.

  89. Sun X, Li J, Sica G, Fan SQ, Wang Y, Chen Z, Muller S, Chen ZG, Fu X, Dong XY, Guo P, Shin DM & Dong JT. Interruption of nuclear localization of ATBF1 during the histopathologic progression of head and neck squamous cell carcinoma. Head Neck 35:1007-1014, 2013.

  90. Xing C, Fu X, Sun X & Dong JT. Lack of an additive effect between the deletions of Klf5 and Nkx3-1 in mouse prostatic tumorigenesis. J Genet Genomics 40:315-318, 2013.

  91. Xing C, Fu X, Sun X, Guo P, Li M & Dong JT. Different expression patterns and functions of acetylated and unacetylated Klf5 in the proliferation and differentiation of prostatic epithelial cells. PLoS ONE 8:e65538, 2013.

  92. Zhang B, Zhang Z, Xia S, Xing C, Ci X, Li X, Zhao R, Tian S, Ma G, Zhu Z, Fu L & Dong JT. KLF5 activates microRNA 200 transcription to maintain epithelial characteristics and prevent induced epithelial-mesenchymal transition in epithelial cells. Mol Cell Biol 33:4919-4935, 2013.

  93. Zhang Z, Zhu Z, Zhang B & Dong JT. Epigenetic regulation of miRNAs in breast cancer formation and progression. In: F. H. Sarkar (ed.) Epigenetics and cancer, pp. 95-114. New York: Springer, 2013.

  94. Sakata N, Kaneko S, Ikeno S, Yutaka M, Nakabayashi H, Dong XY, Dong JT, Tamaki T, Nakano N & Itoh S. TGFbeta signaling cooperates with AT motif-binding factor-1 (ATBF1) for repression of the alpha-fetoprotein promote. J Signal Transduct 2014:970346 (970311 pages), 2014.

  95. Sun X, Li J, Dong FN & Dong JT. Characterization of nuclear localization and SUMOylation of the ATBF1 transcription factor in epithelial cells. PLoS One 9:e92746, 2014.

  96. Xing C, Ci X, Sun X, Fu X, Zhang Z, Dong EN, Hao ZZ & Dong JT. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways. Neoplasia 16:883-899 Cover article, 2014.

  97. Zhang Z, Zhu Z, Zhang B, Li W, Li X, Wu X, Wang L, Fu L, Fu L & Dong JT. Frequent mutation of rs13281615 and its association with PVT1 expression and cell proliferation in breast cancer. J Genet Genom 41:187-195, 2014.

  98. Amin AR, Karpowicz PA, Carey TE, Arbiser J, Nahta R, Chen ZG, Dong JT, Kucuk O, Khan GN, Huang GS, Mi S, Lee HY, Reichrath J, Honoki K, Georgakilas AG, Amedei A, Amin A, Helferich B, Boosani CS, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bhakta D, Halicka D, Niccolai E, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Bilsland A, & Shin DM. Evasion of anti-growth signaling: a key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Semin Cancer Biol 35:Suppl:S55-77, 2015.

  99. Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AM, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HP, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HM, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, & Zollo M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol 35 Suppl:S276-304, 2015.

  100. Ci X, Xing C, Zhang B, Zhang Z, Ni JJ, Zhou W & Dong JT. KLF5 inhibits angiogenesis in PTEN-deficient prostate cancer by attenuating AKT activation and subsequent HIF1alpha accumulation. Mol Cancer 14:91 (15 pages), 2015.

  101. Li X, Zhang B, Wu Q, Ci X, Zhao R, Zhang Z, Xia S, Su D, Chen J, Ma G, Fu L & Dong JT. Interruption of KLF5 acetylation converts its function from tumor suppressor to tumor promoter in prostate cancer cells. Int J Cancer 136:536-546, 2015.

  102. Sun X, Xing C, Fu X, Li J, Zhang B, Frierson HFJ & Dong JT. Additive effect of Zfhx3/Atbf1 and Pten deletion on mouse prostatic tumorigenesis. J Genet Genomics 42:373-382, 2015.

  103. Zhao H, Gao A, Zhang Z, Tian R, Luo A, Li M, Zhao D, Fu L, Fu L, Dong JT & Zhu Z. Genetic analysis and preliminary function study of miR-423 in breast cancer. Tumour Biol 36:4763-4771, 2015.

  104. Luo A, Su D, Zhang X, Qi L, Fu L & Dong JT. Estrogen-estrogen receptor signaling suppresses the transcription of ERRF in breast cancer cells. J Genet Genomics 43:565-567, 2016.

  105. Luo A, Zhang X, Fu L, Zhu Z & Dong JT. Zinc finger factor ZNF121 is a MYC-interacting protein functionally affecting MYC and cell proliferation in epithelial cells. J. Genet. Genomics 43:677-685, 2016.

  106. Zhang B, Zhao R, He Y, Fu X, Fu L, Zhu Z, Fu L & Dong JT. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR. Oncotarget 7:5702-5714, 2016.

  107. Zhao D, Ma G, Zhang X, He Y, Li M, Han X, Fu L, Dong XY, Nagy T, Zhao Q, Fu L & Dong JT. Zinc finger homeodomain factor Zfhx3 is essential for mammary lactogenic differentiation by maintaining prolactin signaling activity. J Biol Chem 291:12809-12820, 2016.

  108. Qi L, Zhang B, Zhang S, Ci X, Wu Q, Ma G, Luo A, Fu L, King JL, Nahta R & Dong JT. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression. Oncotarget 8:36054-36066, 2017.

  109. Xia S, Lin R, Jin L, Zhao L, Kang HB, Pan Y, Liu S, Qian G, Qian Z, Konstantakou E, Zhang B, Dong JT, Chung YR, Abdel-Wahab O, Merghoub T, Zhou L, Kudchadkar RR, Lawson DH, Khoury HJ, Khuri FR, Boise LH, Lonial S, Lee BH, Pollack BP, Arbiser JL, Fan J, Lei QY, & Chen J. Prevention of dietary-fat-fueled ketogenesis attenuates BRAF V600E tumor growth. Cell Metab 25:358-373, 2017.

  110. Gao A, Sun T, Ma G, Cao J, Hu Q, Chen L, Wang Y, Wang Q, Sun J, Wu R, Wu Q, Zhou J, Liu L, Hu J, Dong JT, & Zhu Z. LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway. Nature Communications 9:4180, 2018.

  111. King JL, Zhang B, Li Y, Li KP, Ni JJ, Saavedra HI & Dong JT. TTK promotes mesenchymal signaling via multiple mechanisms in triple negative breast cancer. Oncogenesis 7:69, 2018.

  112. Luo A, Zhang K, Zhao Y, Zhu Z, Fu L & Dong JT. ZNF121 interacts with ZBRK1 and BRCA1 to regulate their target genes in mammary epithelial cells. FEBS Open Bio 8:1943-1952, 2018.

  113. Tao R, Zhang B, Li Y, King JL, Tian R, Xia S, Schiavon CR & Dong JT. HDAC-mediated deacetylation of KLF5 associates with its proteasomal degradation. Biochem Biophys Res Commun 500:777-782, 2018.

  114. Tian X, Tao F, Zhang B, Dong JT & Zhang Z. The miR-203/SNAI2 axis regulates prostate tumor growth, migration, angiogenesis and stemness potentially by modulating GSK-3beta/beta-CATENIN signal pathway. IUBMB Life 70:224-236, 2018.

  115. Zhao D & Dong JT. Upregulation of long non-coding RNA DRAIC correlates with adverse features of breast cancer. Noncoding RNA 4, 2018.

  116. Hu Q, Zhang B, Chen R, Fu C, A J, Fu X, Li J, Fu L, Zhang Z & Dong JT. ZFHX3 is indispensable for ERβ to inhibit cell proliferation via MYC downregulation in prostate cancer cells. Oncogenesis 8:28, 2019.

  117. Ji PY, Li ZY, Wang H, Dong JT, Li XJ & Yi HL. Arsenic and sulfur dioxide co-exposure induce renal injury via activation of the NF-kappaB and caspase signaling pathway. Chemosphere 224:280-288, 2019.

  118. Ma G, Gao A, Yang Y, He Y, Zhang X, Zhang B, Zhang Z, Li M, Fu X, Zhao D, Wu R, Qi L, Hu Q, Li J, Fu L, Zhu Z, & Dong JT. Zfhx3 is essential for progesterone/progesterone receptor signaling to drive ductal side-branching and alveologenesis in mouse mammary glands. J Genet Genomics 46:119-131, 2019.

  119. Peng W, Guo L, Tang R, Liu X, Jin R, Dong JT, Xing CG & Zhou W. Sox7 negatively regulates prostate-specific membrane antigen (PSMA) expression through PSMA-enhancer. Prostate 79:370-378, 2019.

  120. Wu Q, Fu C, Li M, Li J, Li Z, Qi L, Ci X, Ma G, Gao A, Fu X, A J, An N, Liu M, Li Y, King JL, Fu L, Zhang B, & Dong JT. CINP is a novel cofactor of KLF5 required for its role in the promotion of cell proliferation, survival and tumor growth. Int J Cancer 144:582-594, 2019.

  121. Zhao D, Han X, Huang L, Wang J, Zhang X, Jeon JH, Zhao Q & Dong JT. Transcription factor ZFHX3 regulates calcium influx in mammary epithelial cells in part via the TRPV6 calcium channel. Biochem Biophys Res Commun 519:366-371, 2019.

  122. Fu C, An N, Liu J, A J, Zhang B, Liu M, Zhang Z, Fu L, Tian X, Wang D & Dong JT. The transcription factor ZFHX3 is crucial for the angiogenic function of hypoxia-inducible factor 1α in liver cancer cells. J Biol Chem In press, 2020.

  123. Guo P, Xing C, Fu X, He D & Dong JT. Ras inhibits TGF-beta-induced KLF5 acetylation and transcriptional complex assembly via regulating SMAD2/3 phosphorylation in epithelial cells. J Cell Biochem 121:2197-2208, 2020.

  124. Li J, Zhang B, Liu M, Fu X, Ci X, A J, Fu C, Dong G, Wu R, Zhang Z, Fu L & Dong JT. KLF5 Is crucial for androgen-AR signaling to transactivate genes and promote cell proliferation in prostate cancer cells. Cancers (Basel) 12:748, 2020.

  125. Li Y, Zhang B, Xiang L, Xia S, Kucuk O, Deng X, Boise LH & Dong JT. TGF-β causes docetaxel resistance in prostate cancer via the induction of Bcl-2 by acetylated KLF5 and protein stabilization. Theranostics 10:7656-7670, 2020.

  126. Wu R, Fang J, Liu M, A J, Liu J, Chen W, Li J, Ma G, Zhang Z, Zhang B, Fu L & Dong JT. SUMOylation of the transcription factor ZFHX3 at Lys-2806 requires SAE1, UBC9, and PIAS2 and enhances its stability and function in cell proliferation. J Biol Chem 295:6741-6753, 2020.

  127. Zhang B, Ci X, Tao R, Ni JJ, Xuan X, King JL, Xia S, Li Y, Frierson HF, Lee DK, Xu J, Osunkoya AO & Dong JT. Klf5 acetylation regulates luminal differentiation of basal progenitors in prostate development and regeneration. Nat. Commun. 11:997, 2020.